Skip to main content

Hemophilia B

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
NCT06003387 | PHASE 3 | INTERVENTIONAL

The purpose of this study is to assess the risk of bleeding due to failure of expected pharmacological action of CSL222 in adults with severe or moderately severe hemophilia B with detectable pretreatment AAV5 Nabs.

Trial Information
12 Sites
35 Participants
RECRUITING
18 Years

If interested, contact clinicaltrials@cslbehring.com or +1 610-878-4697 for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

University of Michigan
Ann Arbor,Michigan,United States,48109
Royal Prince Alfred Hospital
Camperdown,New South Wales,Australia,2050
Royal Brisbane Hospital
Herston,Queensland,Australia,4029
The Alfred Hospital
Melbourne,Victoria,Australia,3004
McMaster University Hamilton
Hamilton,Ontario,Canada,L8N3Z5
Sheba Medical Center
Tel Hashomer,Ontario,Israel,5265601
Kyungpook National University Hospital
Daegu,Ontario,Korea, Republic of,41944
Kyung Hee University Hospital at Gangdong
Seoul,Ontario,Korea, Republic of,05278
Severance Hospital, Yonsei University Health System
Seoul,Ontario,Korea, Republic of,3722
Centro de Investigacion Clinica GRAMEL S.C.
Ciudad de México,Distrito Federal,Mexico,3720
King Faisal Specialist Hospital and Research Center
Riyadh,Distrito Federal,Saudi Arabia,11471
Haemophilia Comprehensive Care Centre
Johannesburg,Distrito Federal,South Africa,2193

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov